## Abualbishr Alshreef

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8491588/publications.pdf

Version: 2024-02-01

22 papers 473 citations

8 h-index 17 g-index

23 all docs

23 docs citations

times ranked

23

657 citing authors

#	Article	IF	CITATIONS
1	Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial. Lancet, The, 2016, 388, 356-364.	13.7	168
2	Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial. Lancet Neurology, The, 2019, 18, 821-833.	10.2	116
3	The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation. Health Technology Assessment, 2016, 20, 1-150.	2.8	58
4	Computerised speech and language therapy or attention control added to usual care for people with long-term post-stroke aphasia: the Big CACTUS three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	2.8	24
5	Impact of pelvic floor muscle training on sexual function of women with urinary incontinence and a comparison of electrical stimulation versus standard treatment (IPSU trial): a randomised controlled trial. Physiotherapy, 2018, 104, 91-97.	0.4	22
6	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 2019, 19, 65-74.	1.2	11
7	Provider Payment Mechanisms: Effective Policy Tools for Achieving Universal and Sustainable Healthcare Coverage., 0, , .		10
8	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment, 2021, 25, 1-196.	2.8	10
9	Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II–III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial. PharmacoEconomics - Open, 2017, 1, 175-184.	1.8	9
10	Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. Value in Health, 2020, 23, 928-935.	0.3	9
11	Self-managed, computerised word finding therapy as an add-on to usual care for chronic aphasia post-stroke: An economic evaluation. Clinical Rehabilitation, 2021, 35, 703-717.	2.2	9
12	Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. Pharmacoeconomics, 2021, 39, 913-927.	3.3	6
13	Review of Economic Submissions to NICE Medical Technologies Evaluation Programme. Applied Health Economics and Health Policy, 2016, 14, 623-634.	2.1	5
14	The impact of an intervention to increase uptake to structured self-management education for people with type 2 diabetes mellitus in primary care (the embedding package), compared to usual care, on glycaemic control: study protocol for a mixed methods study incorporating a wait-list cluster randomised controlled trial. BMC Family Practice, 2019, 20, 152.	2.9	5
15	Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers. Medical Decision Making, 2019, 39, 910-925.	2.4	5
16	Increasing uptake of structured self-management education programmes for type 2 diabetes in a primary care setting: a feasibility study. Pilot and Feasibility Studies, 2020, 6, 71.	1.2	3
17	Assessing the Appropriateness of Existing Model Adaptation Methods for Low and Middle-Income Countries. Value in Health, 2018, 21, S8.	0.3	2
18	PIN156 INTRAVITREAL THERAPY WITH RANIBIZUMAB VS AFLIBERCEPT VS BEVACIZUMAB FOR MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION: A WITHIN TRIAL COST-UTILITY ANALYSIS. Value in Health, 2019, 22, S664.	0.3	1

#	Article	IF	CITATIONS
19	Methods to Account for Follow-Up Time Differences when Calculating Qalys from Randomised Controlled Trials. Value in Health, 2015, 18, A711.	0.3	0
20	Conceptual Modelling for Cost-Effectiveness Analysis of Intravitreal Therapy with Ranibizumab, Aflibercept or Bevacizumab for Macular Oedema Due to Central Retinal Vein Occlusion. Value in Health, 2016, 19, A366.	0.3	0
21	Haemorrhoidal Artery Ligation Procedure For The Treatment of Symptomatic Grade II–III Heamorrhoids: A Trial-Based And Long-Term Model-Based Economic Evaluation. Value in Health, 2017, 20, A666.	0.3	O
22	PSS25 MAPPING FROM VISUAL ACUITY TO UTILITY IN PATIENTS WITH MACULAR OEDEMA DUE TO CENTRAL RETINAL VEIN OCCLUSION USING DATA FROM THE LEAVO TRIAL. Value in Health, 2019, 22, S891.	0.3	0